A prospective, non-randomized study of home-use of mifepristone for medical abortion in the U.S.
This prospective, non-randomized, open-label study at six Planned Parenthood centers gave women with pregnancies up to 63 days gestation seeking medical abortion the choice of taking mifepristone in the center or at home. Four hundred women were enrolled in the study, and 32% of those women chose to take mifepristone at home. Ninety-nine percent of home users reported that they would take mifepristone at home again and 96% would recommend home use to a friend. Home use of mifepristone did not increase the burden on service delivery providers.
Access the abstract .